Epigenetische Modifikationen in malignen Zellen

Schlüsselwörter

Epigenetik - DNA-Methylierung - Histone

Keywords

epigenetics - DNA methylisation - histones

Literatur

• 1 Almstedt M, Blagitko-Dorfs N, Duque-Afonso J. et al . The DNA demethylating agent 5-aza-2’- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.  Leuk Res. 2010;  34 899-905
• 2 Borthakur G, Ahdab S E, Ravandi F. et al . Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.  Leuk Lymphoma. 2008;  49 690-695
• 3 Cashen A F, Schiller G J, O’Donnell M R, DiPersio J F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.  Clin Oncol. 2010;  28 556-561
• 4 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.  J Clin Oncol. 2010;  28 562-569
• 5 Fenaux P, Mufti G J, Hellström-Lindberg E. et al . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.  Lancet Oncol. 2009;  10 223-232
• 6 Field T, Perkins J, Huang Y. et al . 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.  Bone Marrow Transplant. 2010;  45 255-260
• 7 Flotho C, Claus R, Batz C. et al . The DNA methyltransferase inhibitors azacitidine, Decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.  Leukemia. 2009;  23 1019-1028
• 8 Garcia-Manero G, Yang H, Bueso-Ramos C. et al . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.  Blood. 2008;  111 1060-1066
• 9 Goodyear O, Agathanggelou A, Novitzky-Basso I. et al . Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.  Blood. 2010;  116 1908-1918
• 10 Hackanson B, Guo Y, Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies.  Expert Opin Ther Targets. 2005;  9 45-61
• 11 Issa J-P J, Kantarjian H M. Targeting DNA methylation.  Clin Cancer Res. 2009;  15 3938-3946
• 12 Kantarjian H, Issa J P, Rosenfeld C S. et al . Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.  Cancer. 2006;  106 1794-1803
• 13 Kornblith A B, Herndon 2nd J E, Silverman L R. et al . Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.  J Clin Oncol. 2002;  20 2441-2452
• 14 Kuendgen A, Schmid M, Schlenk R. et al . The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.  Cancer. 2006;  106 112-119
• 15 Ley T J, Ding L, Walter M J. et al . DNMT3A mutations in acute myeloid leukemia.  N Engl J Med. 2010;  363 2424-2433
• 16 Lübbert M, Bertz H, Rüter B. et al . Non-intensive treatment with low-dose 5-aza-2’- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.  Bone Marrow Transplant. 2009;  44 585-588
• 17 Lübbert M, Suciu S, Baila L. et al . Low-dose decitabine vs. best supportive care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group.  J Clin Oncol. in press 2011
• 18 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.  J Clin Oncol. 2011;  29 475-486
• 19 Möller I, Blum S, Gattermann N at al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.  Ann Hematol. 2009;  88 1141-1144
• 20 Silverman L R, Demakos E P, Peterson B L. et al . Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.  J Clin Oncol. 2002;  20 2429-2440
• 21 Wagner J, Hackanson B, Lübbert M. et al . Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.  Clin Epigenet. 2010;  1 117-136